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Abstract
Background: Data on encephalitis in Thailand have not been completely described. Etiologies remain largely
unknown. We prospectively analyzed 103 Thai patients from 27 provinces for the causes of encephalitis using
clinical, microbiological and neuroimaging indices; caseswithout a diagnosis were evaluated for autoimmune
causes of encephalitis.
Methods: Patients with encephalitis and/or myelitis were prospectively studied between October 2010 and August
2012. Cases associated with bacterial, rickettsial and mycobacterial diseases were excluded. Herpes viruses 1-6 and
enteroviruses infection was diagnosed using PCR evaluation of CSF; dengue and JE viruses infection, by serology.
The serum of test-negative patients was evaluated for the presence of autoantibodies.
Results: 103 patients were recruited. Fifty-three patients (52%) had no etiologies identified. Twenty-five patients
(24%) were associated with infections. Immune encephalitis was found in 25 (24%); neuropsychiatric lupus
erythematosus (4), demyelinating diseases (3), Behcet’s disease (1) and the remaining had antibodies to NMDAR
(5), ANNA-2 (6), Yo (2), AMPA (1), GABA (1), VGKC (1) and NMDA coexisting with ANNA-2 (1). Presenting symptoms
in the autoimmune group included behavioral changes in 6/25 (versus 12/25 in infectious and 13/53 in unknown
group) and as psychosis in 6/25 (versus 0/25 infectious and 2/53 unknown). Seizures were found in 6/25 autoimmune,
4/25 infectious and 19/53 unknown group. Two patients with anti-ANNA-2 and one anti-Yo had temporal lobe
involvement by magnetic resonance imaging. Two immune encephalitis patients with antibodies to NMDAR and
ANNA-2 had ovarian tumors.
Conclusions: Autoantibody-associated encephalitis should be considered in the differential diagnosis and
management algorithm regardless of clinical and neuroimaging features.
Keywords: Encephalitis, Autoimmune encephalitis, Paraneoplastic encephalitis, Limbic encephalitis
Background
The priority in managing encephalitis is to first exclude
infectious causes, many of which are effectively treated
using antimicrobial agents. Non-infectious causes of
encephalitis due to autoimmune and paraneoplastic
etiologies, are also a diagnostic priority as these syndromes
may be life-threatening, are often associated with an
underlying malignancy or systemic disease, and may be
treatable if diagnosed early. Despite dramatic advances in
identifying the protean causes of encephalitis, a significant
proportion of cases still defy diagnostic work-up. Recent
international studies reported greater than 50% of
encephalitis patients as have no etiology identified,
despite extensive evaluation [1,2]. The California En-
cephalitis Project (CEP) initiated in 1998 [3] reported that
25% of 334 patients had confirmed or possible infectious
etiologies, whereas 208 cases (62%) lacked a diagnosis.
Although patients with lymphocytic and normal glucose
cerebrospinal fluid (CSF) profile are usually suspected
to have a viral meningoencephalitis, there is growing
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CSF profile autoantibody-associated encephalitis.
In 2004, Thieben et al published a series of 7 patients
with potentially reversible autoimmune limbic encephalitis
associated with neuronal potassium channel antibody
[4]. Vincent et al reported another 10 cases with limbic
encephalitis associated with low plasma sodium that
were identified as potassium channel antibody-associated
encephalopathy [5]. These publications are among the
earliest studies to emphasize the significance of neuronal
autoantibodies in aseptic encephalitis. After the discovery
of antibody to N-methyl-D-aspartate receptor (NMDAR)
in 2007 [6], there have been additional reports of
immune-mediated encephalitis. The first case series of
anti-NMDAR limbic encephalitis included 12 women
with prominent psychiatric symptoms [6]. Ten of 20
encephalitis patients with unidentified etiologies in CEP
(The California Encephalitis Project) were later found to
have anti-NMDAR antibody [7]. These patients (6 females
and 4 males) were young adults (mean age 18.5 year)
who primarily presented with dyskinesia and psychiatric
manifestations [7]. Subsequent CEP study (2007-2010)
demonstrated that encephalitis associated with anti-
NMDAR antibody (32 of 761) was nearly as common
as viral causes (47 of 761) in patients less than 30 years
of age [8]. Seizures, language and autonomic dysfunctions,
movement disorder and psychoses were predominating
clinical features in these patients [9].
A report from Malaysia [10] revealed that 8 of 16 adult
encephalitis patients (14-29 years of age) and 2 children
(both 9 years old) with dominant psychiatric features had
anti-NMDAR antibody yet lacked evidence of underlying
tumor. Autoantibody-associated encephalitis other than
anti-NMDAR is now increasingly reported [7,8]. These
patients can present with a wide range of manifestations
unrelated to solid tumors and are distributed across a
wider age group. These reports have confirmed the
incidence and severity of immune-mediated encephalitis
in non-infectious cases of encephalitis.
We prospectively studied 103 Thai patients between 2
and 85 years of age, presenting with clinically non-bacterial,
non-rickettsial, non-TB, non-fungal and non-parasitic
encephalitis and/or myelitis with normal or lymphocytic
CSF profile who were evaluated by the Neurology service
of King Chulalongkorn Memorial Hospital (KCMH)
between October 2010 and August 2012. Eleven pediatric
patients aged one to fourteen years seen over the same
period were included in this study.
Methods
Study design
This prospective study of patients with clinical evidence
of encephalitis was conducted at KCMH, a tertiary refer-
ral hospital. Seventeen hospitals in Bangkok, Chonburi,
Nakhonpatom and Ayutthaya provinces recruited patients.
The study was approved by the KCMH ethics committee
(reference number 015/2011). Informed consent was
obtained from all patients in written form; when patients
were impaired or underage, consent was obtained from
a family member, parent or guardian. Only patients with
clinical evidence of encephalitis and/or myelitis with or
without peripheral nerve involvement were included. Pa-
tients with laboratory evidence of infectious encephalitis,
e.g. viral, bacteria, mycobacterium tuberculosis (TB),
parasite or rickettsia were excluded. Only patients who
were normocellular or showed lymphocytosis with normal
or slightly decreased glucose in CSF were enrolled.
Patients with low CSF glucose and who had no evidence
of viral, bacterial, TB, fungal, or parasitic infection and
patients without evidence of malignant cells after cyto-
centrifugation were included. Magnetic resonance imaging
(MRI) of the brain and/or spinal cord was performed
within 48-72 hours of admission. In patients with unstable
clinical conditions, computed tomography (CT) scan was
performed instead of MRI.
Definition
Encephalitis was defined as a clinical syndrome comprising
of headache, impaired cognitive function or consciousness,
seizures or other focal deficits in the presence of an imaging
study consistent with brain dysfunction. Myelitis was also
included since it may be a sole manifestation or presenting
feature subsequently followed by involvement of other
structures. Myelitis was defined as fever and/or evidence
of spinal cord dysfunction manifesting as sensori-motor
deficits or pure motor deficit with or without sphincter
involvement. Onset of the disease was defined as acute
when neurological symptoms appeared at onset of any
symptoms or within 7 days of a prodrome. They were
subacute when appearing 8-30 days after prodrome and
chronic if the interval was longer than 30 days.
All suspected cases of central nervous system infection
with bacteria, fungi, parasites or mycobacteria were
excluded as well as encephalopathy secondary to sepsis
or systemic inflammatory response syndrome.
Investigations
Investigations included routine CBC, BUN, Cr, serum
electrolytes, HIV antibody, chest X-Ray and liver function
studies. Blood cultures were performed in all febrile case.
Immunofluorescence assays for rickettsia were performed
on serum when appropriate. All CSF was examined using
cytology, glucose and protein levels, and cryptococcal
antigen determination. PCR was used to evaluate CSF
for herpes simplex virus (HSV) varicella zoster virus
(VZV), Epstein Barr virus (EBV), cytomegalovirus (CMV),
human herpes virus 6 (HHV-6) and enteroviruses. Patients
with a history of animal bites and/or those with signs or
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extracted hair follicles tested for rabies viral RNA.
Serologies for Japanese Encephalitis virus (JEV) and
dengue virus were performed using IgM capture methods
[11]. When indicated by MRI and by initial-negative
serology studies, patients were evaluated for Nipah, Hendra
and West Nile Virus (WNV) by PCR and paired acute
and convalescent serology studies. MRI was performed
for all cases unless the patient was unstable. MR studies
were performed with a 3-T MR imager (Phillip MR systems
Achieva Release 2.6.3.7) at Phyathai 2 Hospital and a 3-T
H o r i z o nM Ri m a g e r( G EM e d i c a ls y s t e m s )a tK C M H .
Contrast-enhanced studies were obtained using intraven-
ous gadopentetate dimeglumine.
Detection of autoantibodies
Examination for autoantibodies was performed on archived
serum of all patients admitted between October 2010
and June 2011 who presented with a negative work-up
for infectious etiologies. Routine autoantibody testing
was initiated in June 2011 after infection had been
ruled out by laboratory studies and extended culture.
Testing for autoantibodies was completed within 7-14
days. Twenty autoimmune and paraneoplastic neuro-
logical syndrome (PNS) related antibodies consisting of
anti-NMDAR, anti-AMPA (2-amino-3-(5-methyl-3-oxo-
1,2- oxazol-4-yl) propanoic acid)-1 and 2 receptor, anti-
CASPR2 (contactin-associated protein 2), anti-LGI-1
(Leucine-rich, glioma inactivated 1), anti-GABA (gamma-
aminobutyric acid)-A and B receptor, anti-Hu (ANNA-1),
anti-Ri (ANNA-2), anti-Yo (PCA-1), PCA-2, anti-Tr, anti-
MAG, anti-myelin, anti-GAD, anti-CV2 (CRMP5), anti-
ampiphysin, anti-neuroendothelium, anti-GFAP, anti-
synaptophysin and AGNA/anti-SOX1 were determined
by indirect immunofluorescence (IIF) assay in sera using
EUROIMMUN
W (Germany). Briefly, serum was diluted 10-
fold and incubated on slides containing either individual
antigens expressed in HEK cells or specific tissues (cere-
bellum, pancreas, intestine and nerve cell) followed by
the second antibody conjugated with fluorescence iso-
thiocyanate (FITC). Immunofluorescence was assessed
using an inverted fluorescen c em i c r o s c o p e( O l y m p u s ® ,
model IX81). Assay for neuromyelitis optica (NMO)
antibody was performed using standard IIF technique
[12]. The diagnosis was confirmed using immunoblot
analysis against five autoantibodies (antibodies against
anti-amphiphysin, anti CV2, anti-Ri, anti-Yo and anti-
Hu). Patient’s serum was diluted 1:100 and incubated
with coated test strips followed by co-incubation of en-
zyme conjugate with alkaline phosphatase labeled anti-
human IgG and substrate. The incubated test strips
were evaluated using the EUROLineScan® software pro-
vided by the manufacturer.
Results
One-hundred eleven patients with encephalitis and/or
myelitis were enrolled between October 2010 and August
2012. Sixty-six patients were admitted to KCMH and 45
represented referrals from 17 hospitals, primarily central
Thailand. Eight patients were excluded after investigation
showed alternative diagnoses (cerebral infarction, meta-
bolic encephalopathy, cerebral venous thrombosis and
subarachnoid hemorrhage). Of 103 patients, presentations
included encephalitis (82,79.6%), myelitis (11,10.7%),
encephalomyelitis (4,3.9%), meningoencephalitis (3,2.9%),
encephalomyeloradiculitis (2, 1.9%) and myeloradiculitis
(1,1%). Demographic data are summarized in Table 1.
Patients were categorized into infectious, immune-
mediated and unidentified groups. There were 25 patients
(24.3% of 103) in the infectious group; HSV-1 (6,24%),
VZV (4,16%), JEV (3,12%), fungi (2,8%), mycobacterium
tuberculosis (2,8%), EBV (2,8%), Clostridium tetani (2,8%),
bacteria (1,4%), dengue (1,4%), rabies (1,4%), and dual
infections with HSV-1 and dengue virus (1,4%). Four
cases of TB (2) and fungi (2) were included in this study
because they all had atypical presentations that we could
not distinguish initially from other viral encephalitis cases.
As for TB cases, one presented with acute onset of fever,
headache and prominent behavioral changes resembling
viral encephalitis. The other patient with TB presented
with acute fever, drowsiness accompanied by hemiparesis
shortly after onset which was not common in TB cases.
None had abnormal chest X-Rays or meningeal enhance-
ment particularly at basal cisterns on CTscan of the brain.
The CSF white blood cell counts were 1,050 and 162
cells/mm
3 respectively with predominant mononuclear
cells and both had CSF protein <200 mg/dl with a
sugar level of 12 and 40 mg/dl respectively. PCR for TB
in CSF was positive in both cases. Two patients with
fungal infections also had atypical manifestations. They
presented with acute alterations of behavior in one case
and brainstem encephalitis with cranial nerve palsies in
another. CSF findings showed white blood cells of 9
and 327 cells/mm
3, sugar levels of 52 and 33 mg/dl,
protein levels of 106 and 61 mg/dl respectively. CSF
India Ink preparations were negative.
The immune-mediated group comprised of 25 cases
(24.3% of 103) consisting of anti-Ri (ANNA2) (6,24%),
anti-NMDAR (5,20%), neuropsychiatric lupus erythe-
matosus (NPLE) (4,16%), demyelinating disease (3,12%),
anti-Yo (PCA-1) (2,8%), neuro-Behcet’s disease (1,4%),
anti-AMPAR (1,4%), anti-GABAR (1,4%), anti-VGKC
(1,4%), and co-existence of anti-NMDAR with anti-Ri
(1,4%). Three demyelinating cases were newly diagnosed
with first attacks of multiple sclerosis or neuromyelitis
optica. All presented with encephalitis syndrome. We
could not differentiate them clinically from other viral or
autoimmune causes.
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results of the workup for immune-mediated and unidenti-
fied etiologies are summarized in Table 2.
Clinical profiles, course and investigation of patients with
immune-mediated causes
Onset of the disease was defined as acute in 17 cases
(58%), subacute 4 cases (21%) and chronic in 4 cases
(21%). Common prodromal symptoms included fever
alone (7, 28%) and fever with associated symptoms (3,
12%). Time between prodrome and onset of neurological
symptoms varied (Table 2). Psychosis was more notable
in the immune group (6, 24%). Behavioral changes were
evident in all groups and seizures were found less com-
monly in groups lacking a confirmed etiology (only 6%).
Although fever appeared at different time points within
each groups, only half of the patients (13 of 25) in the
infectious group reported fever as prodromal symptom.
Interestingly, fever was also found to persist despite
recovery of consciousness and respiratory function in two
patients in the immune-mediated group (1 anti-NMDAR
and 1 anti-Yo).
CSF pleocytosis was presnt in roughly half of the
patients in immune and unidentified groups and up to
80% in the infectious etiology group (Tables 2 and 3).
MRI of the brain was done in all but one patient: a
young male with an unstable clinical condition; CT scan
of the brain was performed in this unstable patient who
had anti-NMDAR antibody and the study result was
normal. Abnormalities confined to temporal lobe and
hippocampus suggesting limbic encephalitis were noted
in one case with anti-Yo and two cases with anti-Ri
antibodies.
Table 3 summarized clinical characteristics, course of
disease and results of investigations and outcome of 25
cases associated with autoimmune markers. An underlying
tumor was found in 3 cases with antibodies to NMDAR
(ovarian teratoma), anti-Yo (germ cell tumor) and ANNA-
2 (ovarian cancer). However, another patient with anti-Yo
encephalitis also had a high serum level of CA-125 despite
a normal CTstudy of the abdomen. The clinical outcomes
of immune-mediated CNS diseases varied from complete
recovery in 1 case (treated with IVIG and concurrent
corticosteroid), partial recovery in 10 (4 treated with
immune-modulating therapy), and 12 cases who remained
severely disabled (5 treated) and death in 2 cases (un-
treated). The following treatments were used in this
series: corticosteroids were given to patients with NPLE
(2), demyelinating disease (1), neuro-Behcet’sd i s e a s e
(1), and NMO (1); plasmapheresis was used to treat
one NMDAR antibody-positive patient and IVIG with
concurrent corticosteroids were used to treat 4 cases
with anti-NMDAR (2) and anti-Yo (2).
Co-existence of anti-NMDAR and –Ri antibodies was
found in one patient: an 18- year-old male who initially
developed hemophagocytic syndrome after salmonella
sepsis and was admitted to the ICU where he had seizures
without focal neurological deficits. His CSF profiles
were within normal limit and MRI demonstrated diffuse
cerebral atrophy. The patient received intravenous anti-
biotics (cephalosporin) andi m p r o v e do v e rt h en e x ts i x
weeks with partial minor disability. Result of anti-Ri
Table 1 Demographic data
Demographic data Unknown cause (53) Immune-mediated cause (25) Infectious cause (25)
Category: meningoencephalitis 1(2%) 0 2(8%)
: encephalitis 41(77%) 20(80%) 21(84%)
: myelitis 7(13%) 3(12%) 1(4%)
: encephalomyelitis 3(6%) 0 1(4%)
: encephalomyeloradiculitis 1(2%) 1(4%) 0
: myeloradiculitis 0 1(4%) 0
Age range: 0–15 yr 4(8%) 4(16%) 3(12%)
:1 6 –60 yr 40(76%) 15(60%) 17(68%)
:6 1 –90 yr 9(16%) 6(24%) 5(20%)
Male: female 32: 21 8: 17 12: 13
Underlying diseases
￿ Normal 38(72%) 15(60%) 19(76%)
￿ Malignancy 3(6%) 1(4%) 0
￿ HIV seropositive 2(4%) 0 4(16%)
￿ Autoimmune disease 1(2%) 5(20%) 1(4%)
￿ Diabetes mellitus 3(6%) 2(8%) 1(4%)
￿ Hematologic disease 0 1(4%) 0
Saraya et al. BMC Neurology 2013, 13:150 Page 4 of 9
http://www.biomedcentral.com/1471-2377/13/150Table 2 Clinical course & investigations
Clinical course & investigations Unknown cause Immune-mediated cause Infectious cause
Prodrome symptoms
￿ Not clearly defined 19(36%) 8(32%) 2(8%)
￿ Headache 1(2%) 2(8%) 5(20%)
￿ Fever 6(11%) 7(28%) 1(4%)
￿ Fever with associated symptoms 18(34%) 3(12%) 12(48%)
￿ URI symptoms 6(11%) 1(4%) 2(8%)
￿ Fatigue ,weight loss 1(2%) 3(12%) 0
￿ Skin rash 1(2%) 1(4%) 3(12%)
￿ Dizziness 1(2%) 0 0
Average duration of prodrome to neuro-symptoms 3 days 3 days 2 days
(0–150 days) (0–180 days) (0–30 days)
Average duration of neuro-symptoms onset to peak 1 days 7 days 3 days
(1–180 days) (1–180 days) (1–60 days)
Presenting symptoms
￿ Worsening headache/neck stiffness 2(4%) 0 0
￿ Hemiparesis 1(2%) 0 1(4%)
￿ Paraparesis/paresthesia 6(12%) 3(12%) 1(4%)
￿ Triparesis 1(2%) 0 0
￿ Quadriparesis 3(6%) 1(4%) 0
￿ Psychomotor retardation/drowsiness 6(12%) 1(4%) 5(20%)
￿ Psychosis with/without seizure 2(4%) 6(24%) 0
￿ Behavioral change with/without seizure 13(26%) 6(24%) 12(48%)
￿ Seizures 19(6%) 6(24%) 4(16%)
￿ Facial weakness 0 0 1(4%)
￿ Stiff-person syndrome 0 1(4%) 0
CSF white cells range: 0–5 cells/mm
3 26(49%) 15(60%) 5(20%)
:6 –50 cells/mm
3 15(28%) 3(12%) 8(32%)
:5 1 –100 cells/mm
3 1(2%) 3(12%) 1(4%)
: 101–500 cells/mm
3 6(11%) 1(4%) 3(12%)
: >500 cells/mm
3 2(4%) 0 4(16%)
CSF protein range : 0–30 mg/dl 11(21%) 7(28%) 3(12%)
:3 1 –60 mg/dl 19(36%) 7(28%) 6(24%)
:6 1 –100 mg/dl 9(17%) 5(20%) 6(24%)
: >100 mg/dl 10(19%) 3(12%) 5(20%)
CSF glucose range: 0–30 mg/dl 1(2%) 1(4%) 2(8%)
:3 1 –60 mg/dl 15(28%) 10(40%) 6(24%)
:6 1 –100 mg/dl 26(49%) 8(32%) 12(48%)
: >100 mg/dl 7(13%) 3(12%) 0
￿ Neuroimagings: available 44 24 23
￿ Normal 7(15.9%) 3(12.5%) 1(4.3%)
￿ Midline structures* 3(6.8%) 2(8.3%) 1(4.3%)
￿ Midline structures plus** 3(6.8%) 0 7(30.4%)
￿ White matter lesions 4(9.1%) 3(12.5%) 0
￿ Cortical lesions 8(18.2%) 4(16.7%) 4(17.5%)
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discharge and no immunotherapy was ever initiated.
The relationship between salmonella septicemia and
auto-antibodies may be coincidental. Interestingly, this
case also demonstrated moderately severe cortical atro-
phy for his age.
Anti-Ri (ANNA2) antibody, directed against neuron
oncological ventral antigens (NOVA-1 and NOVA-2)
[13,14], was the most common autoantibody identified
in this study (24% of immune-mediated cases). These
markers were previously reported in patients presenting
with opsoclonus, cerebellar ataxia, limbic encephalitis,
brainstem encephalitis, myelopathy and dementia [15-17],
nearly all cases in our study presented with seizures, and
underlying malignancy was found in one case (ovarian
cancer).
Anti-Yo (PCA-1) targeted CDR2 [18] peptides that are
involved in DNA transcription. The inflammatory process
against this 52 kDa antigen mediated by CD8 cytotoxic T
lymphocytes [18,19] was identified in the cerebellum,
brainstem, spinal cord and spinal nerve roots [20,21].
Such patients usually presented with cerebellar ataxia
and associated malignancies such as ovary, breast or
small cell lung cancer [15,16]. However, none of our
patients presented with ataxia.
Anti-GABABR-antibody has been reported in patients
with limbic encephalitis (LE) associated with small-cell
lung cancer (SCLC). These patients usually present with
intractable seizures [22]. This antibody has been demon-
strated to target the B1 subunit extracellular domain of
GABA receptor [23]. This syndrome most commonly
presents with subacute onset among patients in their sixth
decade of life. Our case presented at 70 years of age, and
with behavioral changes and seizures.
AMPAR is a subtype of glutamate receptor implicated
in excitatory neurotransmission of the brain. This receptor
consists of 4 subunits, but only antibodies to GluR1 and
GluR2 subunits are associated with limbic encephalitis in
patients with thymoma, breast cancer and lung carcinoma
[24]. Most of the cases previously reported with anti-
AMPAR antibody were females over 50 years of age [25],
however our single patient with anti-AMPAR was a 2-
year-old girl who presented with stiff-person syndrome.
Anti-GAD and anti-ampiphysin antibodies in this case
were negative. However, we have not tested anti-glycine
receptor antibody, which has also been reported in stiff
person syndrome. It is also possible that anti-AMPAR
antibody in this case could be associated with viral infec-
tion suggested by the history of antecedent skin rashes.
There are 2 main targets of autoantibodies to VGKC;
one at LGI1 protein and another at CASPR2 [26]. Anti-
bodies against VGKC complexes are rarely associated
with malignancies [27]. CASPR2 is largely found at the
juxtaparanodal region of myelin [28]. This may explain
why circulating antibody of CASPR2 can be associated
with neuromyotonia, for example, as part of Morvan’s
disease [29]. However, one case with anti-CASPR2 in
our series manifested with solitary encephalitis instead
of peripheral nervous system symptoms.
Discussion
The results of our study confirm that autoantibody-
associated encephalitis was as common as infectious
encephalitis in our Thai cohort. These results are similar
to the CEP result [8] and encephalitis studies from other
regions [9,10,30]. However, in our study we found that this
entity was not confined to young adults less than 18 years
of age as previously reported [8]. The average ages of our
patients with anti-NMDAR- and ANNA-2 antibodies were
different; 39 and 67 years respectively. The presence of
autoantibodies other than anti-NMDAR strongly support
that the search for immune-mediated causes of encephal-
itis should not be limited to anti-NMDAR antibody alone.
Clinically, it is extremely difficult to distinguish between
immune-mediated and infectious encephalitis. Immune
mediated diseases such as NPLE, disease of white matter
such as acute post-infectious encephalitis, NMO and
neuro-Behcet’s disease should also be considered in
patients with encephalomyelitis. This includes CNS
vasculitis of both immune and infectious origin and
mitochondrial encephalopathy, the latter of which can have
MRI disturbances similar to herpes simplex encephal-
itis [30]. Furthermore, several autoantibodies, including
those unrelated to malignancy, can be associated with
this syndrome. We also could not exclude the presence
of prior undetected viral, bacterial or parasitic infections
Table 2 Clinical course & investigations (Continued)
￿ Multifocal lesions*** 8(18.2%) 3(12.5%) 3(13%)
￿ Meninges 5(11.4%) 1(4.2%) 4(17.5%)
￿ Miscellaneous**** 2(4.5%) 7(29.1%) 2(8.7%)
￿ Myelopathy 4(9.1%) 1(4.2%) 1(4.3%)
*midline structures referred to brainstem, thalami, basal ganglia, corpus callosum, periventricular white matter, and vermis.
**midline structures plus referred to involvement of midline structures and peripheral lesion in the cerebral hemisphere, cortical gray and white matter,
subcortical white matter, and cerebellum.
***multifocal lesions referred to lesions that involved more than one of these following compartments; brain parenchyma, spinal cord and meninges.
****miscellaneous referred to non-specific lesions such as non-specific white matter changes, aging brain etc.
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Clinical
course & investigations
NMDA Demyelinating
diseases/NMO
AMPA Behcet ANNA2 (anti-Ri) GABA NMDA
+ANNA2
VGKC Anti-Yo NPLE
Encephalitis: myelitis 4: 1 1: 2 0: 1 0: 1 5: 1 1: 0 1: 0 1: 0 2: 0 3: 1
Average age (yr) 39 52 2 33 67 70 18 67 16 31
(5–43) (8–56) (25–82) (11–21) (23–50)
Female: male 4: 1 3: 0 1: 0 2: 0 3: 3 0: 1 0: 1 0: 1 1: 1 4: 0
Underlying disease ovarian teratoma (1) - - - DM(1), SLE(1)
Ovarian cancer (1)
alcoholic
cirrhosis
hemophagocytic
syndrome
DM Germ cells
tumor (1)
SLE (4)
Prodrome symptoms headache (2),
fever (1)
fever (1) fever with
rash
- fever (2), URI (1), - fever fever+
headache
fever (1),
headache (1)
fever (2), weight
loss (1), fatigue+
rash+ alopecia (1) anorexia (1)
Presenting symptoms psychosis+seizure (3),
behavior change (1),
quadripa resis (1)
behavior
change±Seizure
(2), drowsy (1)
parkinsonism (1)
stiff
person
para
paresis
psychosis±seizure
(2), Seizure (3),
para paresis (1)
behavior
change+
Seizure (1)
seizure (1) behavior
change+
Seizure (1)
behavior change (1),
seizure (1)
behavior change (1),
psychosis (1), seizure (1),
paraparesis (1)
Average
CSF wbc 32 5 0 157 1 0 0 0 30 0
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(mg/dl) (19–242) (30–66) (2–68) (42–45) (28–142)
Average CSF sugar (mg/dl) 62 73 59 40 83 71 53 149 70 65
(44–102) (27–104) (50–95) (67–73) (47–82)
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response.
Immune-mediated encephalitis in our series was found
in both sexes and in young and old patient alike (range
1-82 years of age). The majority of cases presented with
an acute to subacute course. Fever was present in both
immune and infectious cases of encephalitis. Psychosis
was the single parameter more likely to be found in the
immune mediated (24%) rather than infectious groups
where there were none. Psychosis was found in 3 of 5
patients with antibody to NMDAR, 2 of 6 ANNA-2 and 1
of 4 NPLE. Seizures were found in both groups. Headache
was slightly more prominent in the infectious group (20%
versus 8%).
Although normocellular CSF (0-5 cells/mm
3) can be
found in 60% of immune cases (versus 20% of patients
with infection), it should not be used as a solitary criteria
for diagnosis because as many as 8 of 28 patients (29%)
with PCR-confirmed HSV encephalitis had no CSF pleo-
cytosis (Saraya, et al. manuscript in preparation).
Neuroimaging failed to aid in the diagnosis of immune
encephalitis. Results varied and abnormalities were usually
confined to the cortical and subcortical regions, whereas
those associated with infection tended to involve midline
and posterior fossa structures (data not shown). MRI
presentation of limbic involvement, previously reported
in association with antibodies against synaptic or neuronal
surface proteins or intracellular antigens, was found in
only 2 cases in this series.
An underlying tumor or malignancy was documented
in only 3 patients. However, search for malignancy was
not conducted in all cases since laboratory results were
known after discharge and the patients were too disabled
or the patient or families’ refused to participate in add-
itional investigations.
Conclusion
The results from this study should encourage physicians
to aggressively screen for immune causes of encephalitis
in all patients with a negative work-up for infectious
encephalitis. Efforts should be made to expedite iden-
tification of autoantibodies as soon as possible, as de-
lays in treatment may allow patients to progress to
coma and/or require intensive medical care including
mechanical ventilation. Ventilator associated infection or
other iatrogenic complications will likely be minimized if
appropriate treatment is applied in a timely manner. The
high prevalence and significant morbidity of auto-
immune encephalitis (24% in our study and 21% in a
recent study from England) coupled to the successful
treatment experience using immune-modulating ther-
apy, make the diagnosis of immune encephalitis a
priority in all patients presenting with suspected
non-infectious encephalitis.
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